Novocure Limited · NASDAQ:NVCR

Novocure — Investor Presentation (August 2023)

41 slides from Novocure's investor presentation, August 2023

  1. Slide 1: Novocure August 2023

    novecure’ yor M oo ‘ . SE ale Soh a Novocure August 2023 patientforward

  2. Slide 2: Forward-looking statements

    novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a

  3. Slide 3: Together with our patients, we strive to extend survival

    together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward”

  4. Slide 4: Tumor Treating Fields are electric fields that exert physical forces to kill cancer cells

    novecure’ Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells GRAVITATIONAL FIELDS MAGNETIC FIELDS ELECTRIC FIELDS exert force on masses exert force on iron & exert force on charges & other magnets polarized molecules =) + @M@ + 4 Lt x x a Ll L K g ,

  5. Slide 5: The cell membrane is a capacitor

    novocure’ the cell membrane |s a capacitor TUNED ELECTRIC FIELDS DISRUPT PROTEINS DURING CELL DIVISION CAUSING CANCER CELL DEATH tumor cell healthy cell patientforwa rd” © 2023 Novocure GmbH 5

  6. Slide 6: TTFields have multiple, distinct mechanisms of action

    novecure’ TT Fields have multiple, distinct mechanisms of action interference of disruption of 4 = , mitosis “ E mechanisms work together to selectively target and disrupt the progression of cancer cells, which can lead downregulation of . to their death > ar downstream L enhancement of cell movemen

  7. Slide 7: Optune indication for adult GBM patients

    Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

  8. Slide 8: Glioblastoma: malignant brain cancer

    novecure’ glioblastoma: malignant brain cancer WHO grade 4 15,000 cases diagnosed in the U.S. each yeart 49.1% of primary malignant brain tumors? 14.6 to 16.7 months median overall survival® 65: median age of newly diagnosed GBM patient? Early detection is nearly ; 5-10% five-year survival rate impo

  9. Slide 9: Optune: proven to extend patient survival

    novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) na Hiticnonsin-2o9,andomssirinonts) —_%09__ 60 NEARLY HALF Log-rank P-value <0,001 ° f ea le vein —_ 087 HR (95% Cl) 0.63 (0.53-0.76) 43% 3 ee Re < o74 e

  10. Slide 10: Optune: greater exposure increased survival

    novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<005 gw Optune + TMZ 4 = TMZ al Bo montnsroes — OF PATIENTS RECEIVED A SURVIVAL M18 months 00s BENEFIT FROM OPTUNE BECAUSE | socom THEY USED IT >50% OF THE TIME i?)

  11. Slide 11: A comprehensive strategy for long-term growth

    novecure’ a comprehensive strategy for long-term growth drive commercial advance deliver adoption clinical trials product innovation in approved to reach new patient to increase dose and indications populations duration of therapy Built upon a foundation of financial strength and a robust intellectu

  12. Slide 12: Drive commercial adoption

    novecure’ drive commercial adoption patientfo rward” © 2023Novocure GmbH 12

  13. Slide 13: An established commercial business in GBM

    an established commercial business in GBM 10 ACTIVE MARKETS SWEDEN FRANCE,,/ GERMANY. CANADA CHINA’ 5 @) @ M SWITZERLAND > AUSTRIA UNITED STATES Gia aren COVERED LIVES GLOBALLY 5,900+ S500M+ ACTIVE PATIENTS ON THERAPY ANNUAL NET REVENUES patientfo rward™ © 2023 Novocure GmbH 13

  14. Slide 14: Comprehensive approach to drive penetration in established markets

    comprehensive approach to drive penetration in established markets patientforward” STRENGTHEN HCP RECOMMENDATION Educate HCPs on benefits of TTFields therapy INCREASE PATIENT DEMAND Arm patients to advocate for Optune® STREAMLINED ORGANIZATION Creation of U.S. CNS Cancers Franchise intended to renew

  15. Slide 15: Advance clinical trials

    novecure’ advance clinical trials patientfo rward” © 2023Novocure GmbH 15

  16. Slide 16: Holistic strategy to expand TTFields clinical footprint

    holistic strategy to expand TT Fields clinical footprint Investigate Expand labels use in new in approved indications L indications Explore additive effects with standards of care

  17. Slide 17: Backbone therapy potential across solid tumors and concurrent therapies

    novecure’ backbone therapy potential with clinical versatility across a range of solid tumors and concurrent therapies IMMUNOTHERAPY Brain a atezolizumab eee 7 ———— = 3) pembrolizumab L wre - >. oS nivolumab ung ... fl RN YY \ a) CHEMOTHERAPY ; N . | ————eo Ovarian RON ea carboplatin THIELDS |: Gepl

  18. Slide 18: Phase 3 LUNAR trial met primary overall survival endpoint

    novecure’ phase 5 LUNAR trial met primary overall survival endpoint Overall survival (ITT population) Overall survival (ICl-treated patients) 10 1.0 09 09 Median OS (months) 13.2 99 Median OS (months) 18.5 10.8 08 Log-rank P-value 0.035, 08 Log-rank P-value 0.03 307 HR (95% Cl) 0.74 (0.56-0.98) 307

  19. Slide 19: Planned commercial pathway to treat NSCLC patients

    novecure’ planned commercial pathway to treat NSCLC patients 0 2023 5 2024 2025 L COMMERCIAL LAUNCH * Activate physici d REGULATORY PATHWAY ee Een an patient education CLINICAL DATA v Initiate pre-PMA discussions programs y, ; with FDA * Treat on-protocol patients ABOUTISSS (eyllnts HESS Y Submit CE

  20. Slide 20: Enrollment complete and pivotal data anticipated in multiple phase 3 trials

    novecure’ enrollment complete and pivotal data anticipated in multiple phase & trials by year-end 2024 MET PRIMARY ENDPOINT ENROLLMENT COMPLETE ENROLLMENT COMPLETE ENROLLMENT COMPLETE ENGOT-ov50/ Zz FN wr OD innovates mers | © manovas Ovarian Cancer + Statistically significant and * Evaluating TTFie

  21. Slide 21: Late-stage pipeline offers significant near-term market expansion opportunity

    novecure’ late-stage pipeline offers significant, near-term market expansion opportunity GLIOBLASTOMA LATE-STAGE PIPELINE 14x CURRENT MARKET OPPORTUNITY PANOVA-3 Pancreatic Cancer $500M+ annual net revenue (2022) METIS Brain Metastasis ENGOT-ov50/ INNOVATE-3 ‘Ovarian Cancer LUNAR Lung Cancer a eo oo

  22. Slide 22: Platform technology driving robust clinical pipeline

    novecure’ platform technology driving robust clinical pipeline TRIAL TTFIELDS THERAPY + PHASE 3 | APPROVED EF-14 temozolomide CNS newly eenosed TRIDENT temozolomide + radiation GUESS Stub) temozolomide + program HaiNousbe pembrolizumab planned recurrent glioblastoma EF-11 monotherapy brain metastasi

  23. Slide 23: Deliver product innovation

    novecure’ deliver product Innovation patientfo rward” © 2023 Novocure GmbH 23

  24. Slide 24: Product roadmap to prioritize dose and efficacy

    product roadmap to prioritize dose and efficacy field generator arrays software applications next gen device new arrays MAXPOINT™ in development treating patients through planning software limited market release in development forward” ©2023 Novocure GmbH 24

  25. Slide 25: Optimized dose delivered can lead to increased efficacy

    novecure’ optimized dose delivered can lead to increased efficacy TUMOR TREATING FIELDS DOSE DELIVERED TIME ON xX FIELD INTENSITY xX CONDUCTIVITY om THERAPY TO TUMOR OF TISSUE —_ patientforwa rd” © 2023 Novocure GmbH 25 Ballo MT, et al. Correlation of Tumor Treating Fields Dosimetry to Survival Outc

  26. Slide 26: New lighter, thinner arrays deliver greater intensity

    novecure’ new lighter, thinner arrays deliver greater intensity an EXISTING ARRAYS NEW ARRAYS AP channel, 1,364 mAmps AP channel, 1,685 mAmps OV/cm LIMITED LAUCH OF NEW ARRAYS NOW IN AUSTRIA AND SWEDEN patientforward™ © 2023 Novocure GmbH 26 ingthe as pa in Atray performance data obtained from pati

  27. Slide 27: Novocure global offices and team

    novocure’ _— SET we strive to extend survival < ee in some of the most aggressive forms of ca GLOBAL OFFICES TEAM MEMBERS innovation focus patientfo rward” da © 2023Novecure Gmibli 27

  28. Slide 28: Appendix

    novocure’ appendix patientforward™

  29. Slide 29: Therapy is frequency-tuned to target dividing cancer cells

    novecure’ therapy is frequency-tuned to target dividing cancer cells | ——— TUMOR TREATING FIELDS 150 kHz 200 kHz Normal ntestine Intestin | | 50kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablatio

  30. Slide 30: Ongoing trial designs

    novecure’ ongoing trial designs - patientfo rward” © 2023 Novocure GmbH 30

  31. Slide 31: LUNAR phase 3 trial in non-small cell lung cancer

    novecure’ LUNAR phase S trial in non-small cell lung cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* three post- progression follow-up visits TTFields + immune checkpoint inhibitor/docetaxel immune checkpoint fg CT q6w until J three post _ 4 survival inhibitor/docetaxel progres follow-up Wishes follow-u

  32. Slide 32: LUNAR-2 phase 3 trial in non-small cell lung cancer

    novecure’ LUNAR-2 phase 3 trial in non-small cell lung cancer OPEN-LABEL RANDOMIZED TRIAL DESIGN CT/follow-up q3w until progression TTFields + pembrolizumab + platinum-based chemotherapy survival follow-up screening and baseline evaluation Gikelonsup q3w until progression STUDY DESIGN ‘an LUNAR-2 +

  33. Slide 33: Ongoing INNOVATE-3 phase 3 trial in ovarian cancer

    novecure’ ongoing INNOVATE-3 phase 3 trial in ovarian cancer OPEN-LABEL, RANDOMIZED TRIAL DESIGN* 5 TTFields + weekly [i = CT/MRI scan q8w survival = paclitaxel | progression follow-up a € 2 survival S weekly paclitaxel 5 follow-up Q ENGOT-ov50/ STUDY DESIGN pared + 540 patients with 18 month minimu

  34. Slide 34: Ongoing METIS phase 3 trial in brain metastases

    novecure’ ongoing METIS phase 3 trial in brain metastases OPEN-LABEL, RANDOMIZED TRIAL DESIGN* stereotactic a 4 radiosurgery screening and baseline ii y stereotactic radiosurgery Tumor Tre Fields Sau MRI q2m until progression MRI q2m until progression randomization 1:1 METIS Brain Metastasis STUDY D

  35. Slide 35: Ongoing PANOVA-3 phase 3 trial in pancreatic cancer

    novocure’ ongoing PANOVA-3 phase 3 trial in panc OPEN-LABEL, RANDOMIZED TRIAL DESIGN! 6 eee : CT q8w until post-PD survival iv ; i follow-up q4w ee iy : eraieltelaiing progression follow up visit pq baseline evaluation " 8 nab-paclitaxel + CT q8w until post-PD survival 8 gemcitabine progression foll

  36. Slide 36: Ongoing TRIDENT phase 3 trial in newly diagnosed GBM

    novecure’ ongoing TRIDENT phase 3 trial in newly diagnosed GBM OPEN-LABEL, RANDOMIZED TRIAL DESIGN* TTFields + RT TTFields + + TMZ maintenance TMZ MRI q8w until survival progression follow-up screening and baseline evaluation TTFields + maintenance TMZ MRI q8w until survival progression follow-up RT

  37. Slide 37: Ongoing KEYNOTE B36 phase 2 trial in NSCLC

    novecure’ ongoing KEYNOTE B36 phase 2 trial in NSCLC OPEN-LABEL RANDOMIZED TRIAL DESIGN* 5 TTFields + mam follow-up q3w, _| survival 4 pembrolizumab CT qow follow-up screening and baseline a evaluation ea z : mem follow-up q3w, fii survival 8 PpennlerretlraurilS CT qow follow-up STUDY DESIGN @ KEYNO

  38. Slide 38: Ongoing KEYNOTE B36 phase 2 trial in NSCLC

    novecure’ ongoing KEYNOTE B36 phase 2 trial in NSCLC OPEN-LABEL, RANDOMIZED TRIAL DESIGN! screening and TTFields (150 kHz) CT/MRI scan q9w until post-progression survival follow-up @ KEYNOTE B36 Lung Cancer baseline evaluation # + pembrolizumab progression or 24 mo follow-up STUDY DESIGN * 66 patien

  39. Slide 39: KEYNOTE D58 builds upon promising data from 2-THE-TOP phase 2 trial

    novecure’ KEYNOTE D58 builds upon promising data from 2-1THE-TOP phase 2 trial ° N=26 patients Median PFS a N=26 patients Median OS 0 f r : 08 2-THE-TOP | 12.1 mos. = os 2-THE-TOP | 25.2 mos. < Gy Wh EF-14 matched-control | 7.9 mos. 2 °7 eal EF-14 matched-control | 15.9 mos. © 06 = 06 4 a \ (HR = 0.

  40. Slide 40: Optune Lua and Optune indications for use and important safety information

    novecure’ Optune Lua® and Optune® indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of a

  41. Slide 41: Optune Lua and Optune warnings and precautions

    novecure’ Optune Lua® and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event

Novocure — Investor Presentation (August 2023) on 6ix